These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30573789)

  • 21. Kinase inhibitors overachieve in CLL.
    Garber K
    Nat Rev Drug Discov; 2014 Mar; 13(3):162-4. PubMed ID: 24549135
    [No Abstract]   [Full Text] [Related]  

  • 22. Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
    Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
    Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
    [No Abstract]   [Full Text] [Related]  

  • 24. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
    Stephens DM
    Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
    Lew TE; Bennett R; Lin VS; Whitechurch A; Handunnetti SM; Marlton P; Shen Y; Mulligan SP; Casan J; Blombery P; Tam CS; Roberts AW; Seymour JF; Thompson PA; Anderson MA
    Blood Adv; 2024 Mar; 8(6):1439-1443. PubMed ID: 38231032
    [No Abstract]   [Full Text] [Related]  

  • 26. Venetoclax in the treatment of chronic lymphocytic leukemia.
    Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
    Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M
    Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venetoclax Yields Strong Responses in CLL.
    Cancer Discov; 2016 Feb; 6(2):113-4. PubMed ID: 26701089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
    Deng R; Gibiansky L; Lu T; Agarwal P; Ding H; Li X; Kshirsagar S; Lu D; Li C; Girish S; Wang J; Boyer M; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
    Clin Pharmacokinet; 2019 Dec; 58(12):1621-1634. PubMed ID: 31209657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABT-199 shows effectiveness in CLL.
    Cancer Discov; 2014 Sep; 4(9):OF7. PubMed ID: 25185206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
    Thompson M; Brander D; Nabhan C; Mato A
    JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABT-199 for chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
    [No Abstract]   [Full Text] [Related]  

  • 33. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.
    Robak E; Jesionek-Kupnicka D; Stelmach P; Kupnicki P; Szataniak M; Robak T
    Ann Hematol; 2022 Jun; 101(6):1387-1392. PubMed ID: 35187604
    [No Abstract]   [Full Text] [Related]  

  • 35. [Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
    Jiang R; Dai LMJ; Sha YQ; Xia Y; Miao Y; Qin SC; Wu W; Qiu JY; Bi HL; Wang L; Fan L; Xu W; Li JY; Zhu HY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):247-250. PubMed ID: 37356988
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
    Roberts AW; Ma S; Kipps TJ; Coutre SE; Davids MS; Eichhorst B; Hallek M; Byrd JC; Humphrey K; Zhou L; Chyla B; Nielsen J; Potluri J; Kim SY; Verdugo M; Stilgenbauer S; Wierda WG; Seymour JF
    Blood; 2019 Jul; 134(2):111-122. PubMed ID: 31023700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Smolej L
    Br J Haematol; 2021 May; 193(4):723-726. PubMed ID: 33216352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv149-iv152. PubMed ID: 28881925
    [No Abstract]   [Full Text] [Related]  

  • 39. New Agents to Treat Chronic Lymphocytic Leukemia.
    Zaman F; Savendahl L
    N Engl J Med; 2016 Jun; 374(22):2185. PubMed ID: 27248632
    [No Abstract]   [Full Text] [Related]  

  • 40. New Agents to Treat Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Seymour JF
    N Engl J Med; 2016 Jun; 374(22):2186-7. PubMed ID: 27248631
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.